Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
6.02
+0.20 (3.44%)
At close: Oct 26, 2026, 4:00 PM EDT
6.05
+0.03 (0.50%)
Pre-market: Oct 27, 2026, 8:59 AM EDT
Myriad Genetics Employees
Myriad Genetics had 2,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Myriad Genetics the 8,542nd largest employer in the world and 1,513th in the United States.
Employees
2,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$298,741
Profits / Employee
-$41,704
Market Cap
575.81M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,700 | 0 | - |
| Dec 31, 2024 | 2,700 | 0 | - |
| Dec 31, 2023 | 2,700 | 100 | 3.85% |
| Dec 31, 2022 | 2,600 | 200 | 8.33% |
| Dec 31, 2021 | 2,400 | -300 | -11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| Castle Biosciences | 1,002 |
| Burning Rock Biotech | 667 |
| Freenome | 381 |
| Biodesix | 334 |
MYGN News
- 5 days ago - Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers - GlobeNewsWire
- 6 days ago - TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations - TheFly
- 6 days ago - Myriad Genetics upgraded to Neutral from Underweight at Piper Sandler - TheFly
- 7 days ago - Myriad Genetics to sell Prenatal Health testing business to Labcorp - TheFly
- 7 days ago - Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp - GlobeNewsWire
- 11 days ago - Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 14 days ago - Myriad Genetics price target raised to $4.50 from $4 at TD Cowen - TheFly
- 19 days ago - Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech - TheFly